Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250646 | 0.84 | ALDH1A1 (0.44) | ALDH1A1LMNAGAARAB9AMAPT | |
| SCHEMBL7249605 | 0.84 | POLB (0.45) | ALDH1A1LMNAGAARAB9AMAPT | |
| SCHEMBL28743311 | 0.83 | ALDH1A1 (0.40) | ALDH1A1LMNAGAARAB9AMAPT | |
| SCHEMBL7248648 | 0.83 | ALDH1A1 (0.44) | ALDH1A1LMNAGAARAB9AMAPT | |
| SCHEMBL7249154 | 0.82 | CA1 (0.44) | ALDH1A1LMNAGAARAB9AMAPT | |
| SCHEMBL7249859 | 0.82 | NPFFR1 (0.52) | ALDH1A1LMNANPFFR1NPFFR2RAB9A | |
| SCHEMBL27573109 | 0.81 | POLB (0.42) | ALDH1A1LMNANPFFR1NPFFR2GAA | |
| SCHEMBL7248229 | 0.81 | NPFFR1 (0.60) | NPFFR1NPFFR2 | |
| SCHEMBL2877082 | 0.73 | NPFFR1 (0.56) | ALDH1A1LMNANPFFR1NPFFR2GAA | |
| SCHEMBL27448810 | 0.73 | HPGD (0.49) | ALDH1A1LMNAGAARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1279667-A | 4(3)-substituted-4(3)-aminonethyl-(thioxo)pyran(thiapyran)or-piperidine derivatives(=gabapendin analogues), their preparation and their use in treatment of neurological disorders | WARNER LAMBERT CO (US) | 2001-01-10 | — | — | CN | claimed |
| EP-1045834-A1 | 4(3)SUBSTITUTED-4(3)-AMINOMETHYL-(THIO)PYRAN OR -PIPERIDINE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-10-25 | — | — | EP | claimed |
| WO-1999031057-A1 | 4(3)SUBSTITUTED-4(3)-AMINOMETHYL-(THIO)PYRAN OR -PIPERIDINE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
| US-6545022-B1 | Treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| CN-1279667-A | 4(3)-substituted-4(3)-aminonethyl-(thioxo)pyran(thiapyran)or-piperidine derivatives(=gabapendin analogues), their preparation and their use in treatment of neurological disorders | WARNER LAMBERT CO (US) | 2001-01-10 | — | — | CN | disclosed |
| EP-1045834-A1 | 4(3)SUBSTITUTED-4(3)-AMINOMETHYL-(THIO)PYRAN OR -PIPERIDINE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999031057-A1 | 4(3)SUBSTITUTED-4(3)-AMINOMETHYL-(THIO)PYRAN OR -PIPERIDINE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |